The skin and mucous membranes are subjected to many disorders and pathological conditions.
The dermatology space is emerging from an active period of diversification and consolidation that has opened up new partnering opportunities over the past five years.
With no shortage of drug approvals, licensing deals, and high-value acquisitions, the dermatology market is generating significant revenues. In 2014 it was worth $17 billion and is forecast to reach almost $19 billion in 2015.
Are you aware that nature offers a wide range of molecules with antioxidant activity able to neutralize, at least in part, the formation of free radicals and therefore counteract the phenomena of cellular aging?
Several natural molecules encapsulated in lipid nanosystems have been considered in the treatment of some skin pathologies or diseases.
Particularly, the use of rosemary and eucalyptus essential oil, saffron derivatives, curcumin, eugenol, capsaicin, thymol, and lycopene has been reported.
The application of lipid nanosystems allows a deep interaction between lipid matrix and skin strata, promoting a prolonged release and efficacy of the loaded natural molecules encapsulated in viscous systems, such as organogels.
NICHE TO MAINSTREAM
Since synthetic drugs for the treatment of skin diseases can induce resistance, it is particularly interesting to use compounds of plant origin, transporting them in pharmaceutical forms capable of controlling their release and absorption.
The use of lipid-based nanosystems for the delivery of natural molecules has proved to be useful in the topical treatment of skin disorders. In fact, it has created a massive market opportunity for the segment. It is attracting many companies to sign deals not only in the medical sector but also in the flourishing cosmetics field.
Lipid Pharmaceuticals launched right before Covid-19 took the world by storm, initially focusing on metabolic indications such as NASH, Prader-Willi Syndrome, and anti-psychotic drug-induced weight gain. Recently, it added dermatology to that list and announced that it has raised more than $20 million.
The funds will provide ample runway on developing Lipidio Pharmaceuticals’ lead candidate, GDD3898, for various indications, including acne, sebaceous hyperplasia, nonalcoholic steatohepatitis (NASH), obesity, and Prader-Willi syndrome and to analyze data from three clinical trials, which the company expects to complete before the end of this year. It is currently in Phase II for acne, Phase I for sebaceous hyperplasia, and Phase I for NASH and obesity.
Founded by David Bullough, Gary Atkinson, Gordon Foulkes, and Raksha Shah, Lipidio Pharmaceuticals is a biopharmaceutical company focused on transforming molecules into the right medicines for dermatological and metabolic diseases.
##funding #biopharm #startup #molecule #transformation #dermatology #metabolicdisease #pharmaceuticals #medical #data #clinicaltrials #applications